Tempus AI Inc. reported strong financial results for the second quarter of 2025, with revenue reaching $314.6 million, an 89.6% increase year-over-year, surpassing analyst estimates of approximately $297 million. The company posted an adjusted loss per share of $0.22, better than the estimated loss of $0.24, and an adjusted EBITDA loss of $5.6 million, showing improvement from previous periods. Gross profit surged 158.3% to $195 million, driven by a 115.3% increase in genomics revenue to $241.8 million and a 36% rise in data and services revenue to $72.8 million. Net loss narrowed significantly to $42.8 million from $552.2 million in the prior year. Tempus AI performed 212,000 next-generation sequencing (NGS) tests during the quarter and increased its cash position by $70 million to $293 million. The company also issued $750 million in 0.75% convertible notes. Following these results, Tempus AI raised its full-year 2025 revenue guidance to approximately $1.26 billion, up from $1.25 billion, representing an 82% year-over-year increase, and projects a positive adjusted EBITDA of $5 million. The CEO cited faster-than-expected growth and improved margins, with clinical volumes accelerating by 30% in the quarter. Analysts have responded positively, with Morgan Stanley maintaining an overweight rating and raising the price target to $68 from $65. The stock price has recently traded above the $65 pivot point, with expectations of further gains.